Alvotech Could Upend Expectations For US Humira Biosimilars
Founder And Chairman Robert Wessman Discusses Firm’s Adalimumab Prospects
Executive Summary
In the second part of an exclusive two-part interview with Generics Bulletin, Alvotech founder and chairman Robert Wessman sets out the firm’s expectations for its rival to Humira, as Alvotech continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.
You may also be interested in...
Humira In 2023: The $17bn Biosimilar Opportunity
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
Humira Biosimilars Prepare For US Competition In 2023
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.
Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone
Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.